Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Metabolic Profile of 14C-Debio 1450 in Healthy Men
NCT02595203Phase 1Completed
- Sponsor
- Debiopharm
- Start
- Nov 2015
- Primary completion
- Dec 2015
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of afabicin in staphylococcal infection (3 cohorts), sponsored by Debiopharm. Primary endpoints: Mass balance recovery at 168 hours, Routes of metabolism and excretion at 168 hours and 2 more. Started Nov 2015; status: completed.
02
Drugs
afabicin
03
Conditions
staphylococcal infection
Beyond the preview
Go deeper on NCT02595203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595203.